Smruti R. Mohanty, M.D

Assistant Professor of Medicine

Dr. Smruti R. Mohanty received his medical degree from Utkal University, India and subsequently moved to USA for advanced medical training. He obtained a Master of Science (MS) degree in community health at Minnesota State University, MN before completing Internal Medicine training at Texas A&M University Health Science Center, TX. He completed Gastroenterology and Hepatology Fellowship training at University of Iowa Hospital and Clinics, IA and University of California, San Diego. Dr. Mohanty’s areas of expertise include hepatology and liver transplantation. His clinical interests focus on evaluation of patients with chronic viral hepatitis, HIV/ HCV/HBV co-infection, cirrhosis of liver, liver cancer, alcoholic cirrhosis, and fatty liver disease including evaluation of patients for liver transplantation. Broadly defined, Dr. Mohanty’s research interests focus on clinical presentation and treatment of Hepatitis B and C, including liver cancer. More specifically, his research focuses on racial and ethnic differences in chronic liver diseases and clinical trials in chronic viral hepatitis B and C and liver cancer.

Chronic hepatitis B is a common and highly infectious disease, which left untreated, may lead to liver cancer and cirrhosis including liver failure. Although current drug treatments do not eradicate the virus, they are effective in suppressing the hepatitis B virus to undetectable levels leading to a need for long-term therapy. Our medical center has participated in several clinical trials involving drugs such as interferon, lamivudine, adefovir and entecavir in the treatment of chronic hepatitis B. Currently, Dr. Mohanty is conducting a clinical trial examining the efficacy of FDA approved drug entecavir in the treatment of hepatitis B in African American and Hispanic populations. In addition, he is involved in the early phases of a clinical trial using gene therapy with the goal to eradicating hepatitis B virus. Success in early phases of the study will be followed by further studies involving large number of Hepatitis B infected patients. If gene therapy is successful in clinical trials then it may revolutionize the treatment of chronic hepatitis B.

Smruti R. Mohanty, M.D.